TPP1: IMPLEMENTING A MODEL OF RISK SHARING OF PHARMACEUTICAL BENEFITS IN PRIMARY CARE  by Gilabert, A et al.
Abstracts 373
PHARMACY ISSUES
TPP1
IMPLEMENTING A MODEL OF RISK SHARING
OF PHARMACEUTICAL BENEFITS IN 
PRIMARY CARE
Gilabert A, Casals A, Sedano E
Catalan Health Service, Autonomous Government of 
Catalonia, Barcelona, Spain
OBJECTIVE: To design and assess a model of risk shar-
ing of pharmaceutical benefits in primary care based on
allocating prescription budgets, assigning prescription
quality standards and linking the results to an economi-
cal benefit.
METHODOLOGY: In 1998 a prescribing budget was as-
signed to primary health care teams (PHCTs) of 22 basic
health areas (BHAs) (488,900 inhabitants). The methodol-
ogy for allocating drug budgets was based on the calcula-
tion of a maximum expenditure permitted (MEP) for each
PHCT by assigning a percent increase above the previous
year’s expenditure, proportionally inverse to its cost/inhab-
itant. This cost/inhabitant was modulated by the percentage
of population with free pharmaceutical coverage (popula-
tion 65 years old or over and other specific population
groups ) and the typology of the BHA (urban or rural). Pre-
scribing quality standards (PQS) assigned for each PHCT
consisted of the intrinsic pharmacological value (IPhV) of
the prescription and the defined daily doses per 1,000 inhab-
itants per year (DHD) for anti-bacterial drugs and NSAIDs.
Values for qualitative indicators were assigned depending
on the distance between the PHCT’s current value and the
group average. Non-achievement of the objectives assigned
for both MEPs and PQSs was linked to a loss of 2% of the
total budget allocation contracted with the PHCT.
RESULTS: The assesment of the prescribing budget ob-
jective showed that 36.4% of PCHTs had an expenditure
below its MEPs and 63.6% over. Of PHCTs exceeding
MEP, 42.9% presented a deviation of less than 5%,
28.6% between 5–10%, 21.4% between 10–15% and
7.1% greater than 15%. Qualitative evaluation showed
that 86.4% of PHCTs achieved the objective of IPhV,
81.8% reached the DHD assigned for anti-bacterials and
68% the DHD for NSAIDs.
CONCLUSION: The model has permitted the Catalan
Health Service to implement the concept of risk sharing
in the management of pharmaceutical benefits in primary
care, and the introduction of greater accountability for
prescription costs in general practice.
TPP2
EVALUATION OF A THERAPEUTIC 
INTERCHANGE PROGRAM FOR CALCIUM 
CHANNEL BLOCKERS IN HYPERTENSION
Nichol MB1, Harada ASM1, Jones J1, Gilderman A2, Salas J2
1University of Southern California, Los Angeles, CA, USA; 
2Prescription Solutions, Costa Mesa, CA, USA
OBJECTIVES: This project evaluated a therapeutic inter-
change program of a pharmacy benefit management firm
that initiated an amlodipine to felodipine therapeutic in-
terchange program. The purpose of this study was to in-
vestigate the effect of switching hypertension therapy in a
group of managed care patients on health-related quality
of life, patient satisfaction, and prescription utilization
and cost.
METHOD: Three groups of managed care patients were
prospectively selected from five large primary care medi-
cal groups in Texas and Oklahoma during the last six
months of 1997. A study group of patients undergoing
interchange (switching from amlodipine to felodipine),
and two comparison groups of patients not undergoing a
medication change were used (continuous amlodipine
and continuous felodipine). Baseline (before a planned
interchange) patient questionnaires were mailed to a total
of 802 patients (Groups 1–3) and eight-week follow-up
(after the interchange) patient questionnaires were mailed
to 295 patients who responded to the first survey. The
patient questionnaires included the SF-36, symptom mea-
sures, and satisfaction with care. Prescription claims data
were used for the utilization and cost analysis.
RESULTS: Patients maintaining therapy on felodipine
continuously were older than amlodipine or switched pa-
tients and were more likely to be female. Switch patients
had lower total prescription utilization after the switch
compared to the continuous-use groups. Switch patients
also had fewer hypertension-related prescriptions after
the switch. There were no statistically significant differ-
ences in quality of life. It appeared that switch patients
were more likely to change hypertension medications af-
ter their initial switch.
CONCLUSIONS: The clear difference in patient charac-
teristics between the treatment groups implies an impor-
tant selection bias. These differences may mean that pa-
tients subject to the therapeutic interchange were selected
for clinical or other reasons not immediately apparent.
Subsequent analyses should control for these effects.
TPP3
PHARMACEUTICAL CARE AND HEALTH
CARE UTILIZATION
Fischer LR, DeFor T, Cooper S, Scott L, Boonstra D, 
Eelkema M, Hase K, Goodman M
HealthPartners, Minneapolis, MN, USA
OBJECTIVES: To assess if pharmaceutical care is associ-
ated with a decrease in overall health care utilization and
cost. Pharmaceutical care entails an expanded role for
pharmacists to provide patient counseling and monitoring
about medications. Few adequately designed studies have
investigated the impact on health care utilization, and, to
date, findings are mixed.
METHODS: A quasi-experimental design, using utiliza-
tion/cost data from an HMO database. Intervention sites
were 3 staff and 3 contract pharmacies. HMO enrollees
with chronic health conditions (lung or heart disease) were
